The studies were performed at a Bio-Safety Level 3 Laboratory (BSL-3) facility in Boston, Massachusetts. The company’s scientists are now designing the protocol for a follow up anti-HIV
GDC-0449 will be evaluated in approximately 150 patients with metastatic colorectal cancer in combination with the current standard of care in a randomized, placebo-controlled, double-blind Phase II trial.
The Cliniporator device has been developed and is manufactured by IGEA (Carpi, Italy). The drug used in most treatments is Bleomycin, a well-known drug in oncology. It’s highly
Based on positive results demonstrated in previous studies of Pyratine-6 (0.1%), for the remediation of photodamaged skin and erythema which included unprecedented reduction in facial redness, in as
GeneCards will be utilized to assist the Japan Patent Office (JPO) in the review and approval of patent applications in the life sciences area. With this agreement, GeneCards
Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study focused on a cell surface
The Gore Reduce clinical study is a prospective, randomized, multi-center, multinational trial designed to demonstrate safety and effectiveness of the Gore Helex Septal Occluder for patent foramen ovale
The revised warning will now read as follows: “The breast cavity must be imaged before implantation to ensure the applicator will fit appropriately. Do not use if the
According to Rick Pauls, DiaMedica’s interim president and CEO, the 20 patient single-blind trial will demonstrate DM-83’s level of effectiveness in controlling blood glucose and insulin levels in
The trial successfully met its objectives of evaluating the safety profile and pharmacokinetic of CF102 single doses, and of determining a dose range for future clinical studies. CF102
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.